Cromatina / Epigenética
Los inhibidores de cromatina/epigenética son compuestos que modulan la estructura y función de la cromatina o interfieren con modificaciones epigenéticas, como la metilación del ADN y la modificación de histonas. Estos inhibidores son herramientas esenciales para estudiar la regulación de la expresión génica y el papel de la epigenética en enfermedades como el cáncer, los trastornos neurológicos y las anomalías del desarrollo. Al dirigirse a los procesos epigenéticos, estos inhibidores pueden alterar los patrones de expresión génica y ofrecer nuevas vías terapéuticas. En CymitQuimica, ofrecemos una amplia selección de inhibidores de cromatina/epigenética de alta calidad para apoyar su investigación en biología molecular, genética y epigenética.
Subcategorías de "Cromatina / Epigenética"
Se han encontrado 2235 productos de "Cromatina / Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KCL-440
CAS:<p>RS 57639 is a bioactive chemical.</p>Fórmula:C18H18N2O2Forma y color:SolidPeso molecular:294.35BPTF-IN-BZ1
<p>BPTF-IN-BZ1 is a BPTF inhibitor that possesses a high potency with a Kd of 6.3 nM.</p>Fórmula:C13H15ClN4OForma y color:SolidPeso molecular:278.74XY153
<p>XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.</p>Fórmula:C33H34FN3O4Forma y color:SolidPeso molecular:555.64JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62Azaphilone-9
CAS:<p>AZA-9 inhibits cancer growth by blocking HuR-ARE RNA binding; IC50=1.2μM.</p>Fórmula:C21H23BrO5Forma y color:SolidPeso molecular:435.3115:0 PG sodium
CAS:<p>15:0 PG sodium serves as an activator for the Protein Kinase C family and is an anionic phospholipid located in the membranes of mitochondria and microsomes. It plays a crucial role in the composition of pulmonary surfactants, especially within the membrane of the pulmonary lamellar bodies.</p>Fórmula:C36H70NaO10PForma y color:SolidPeso molecular:716.90PRMT5-IN-3
CAS:<p>PRMT5-IN-3 is a PRMT5 inhibitor.PRMT5-IN-3 is a combined DNA damaging agent that is synthetically lethal to tumor cells.</p>Fórmula:C22H23F3N4O3Forma y color:SolidPeso molecular:448.44GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Fórmula:C20H18F2N6O5SForma y color:SolidPeso molecular:492.46P300-IN-4
<p>P300-IN-4 (compound 6) is a histone acetyltransferase p300 inhibitor with an IC50 value of 12.2 μM.</p>Fórmula:C29H28ClIN4O5Forma y color:SolidPeso molecular:674.91Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Fórmula:C24H25N7O2Forma y color:SolidPeso molecular:443.50ROPA
CAS:<p>ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.</p>Fórmula:C28H32O6Pureza:98%Forma y color:SolidPeso molecular:464.55CBP/p300-IN-18
<p>CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).</p>Fórmula:C25H27FN4O3Forma y color:SolidPeso molecular:450.51BET-IN-27
CAS:<p>BET-IN-27 (compound 6C) is an orally active BET inhibitor with IC50 values of 3.3 nM (BRD4-BD2), 3.4 nM (BRD4-BD1), 4.1 nM (BRD2-BD1), 20.4 nM (BRD3-BD1), and 42.0 nM (BRDT-BD1). It also exhibits antiproliferative activity.</p>Fórmula:C21H23N5O3SForma y color:SolidPeso molecular:425.5HDAC/Top-IN-1
CAS:<p>HDAC/Top-IN-1, an oral HDAC/Top inhibitor, targets HDAC1-3,6,8 with low IC50s; blocks S-phase & induces apoptosis in HEL cells.</p>Fórmula:C29H25FN4O4Forma y color:SolidPeso molecular:512.53JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Fórmula:C20H15ClF3N3OSForma y color:SolidPeso molecular:437.87BBC0403
CAS:<p>BBC0403 is a BRD2 inhibitor, inhibiting BRD2 and BRD2, and suppresses NF-κB and MAPK signaling pathways.</p>Fórmula:C21H22N2O5Pureza:98.15%Forma y color:SolidPeso molecular:382.41JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Fórmula:C31H31F3N8O4Forma y color:SolidPeso molecular:639.64XP5
<p>XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).</p>Fórmula:C19H25N3O5SForma y color:SolidPeso molecular:407.48(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Fórmula:C20H27ClN6OForma y color:SolidPeso molecular:402.92PARP1-IN-30
CAS:<p>PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.</p>Fórmula:C14H12ClNO4SForma y color:SolidPeso molecular:325.77KSQ-4279 (gentisate)
CAS:<p>KSQ-4279 (gentisate) (Compound Formula I) serves as an effective inhibitor of USP1 and a selective inhibitor of PARP1. This compound shows promise for use in cancer research.</p>Fórmula:C34H31F3N8O5Forma y color:SolidPeso molecular:688.66HIF-1/2α-IN-1
<p>HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.</p>Fórmula:C17H16N6O4Forma y color:SolidPeso molecular:368.35(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37W4275
CAS:<p>W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.</p>Fórmula:C25H36N6O3Forma y color:SolidPeso molecular:468.59GSK789
CAS:<p>GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.</p>Fórmula:C26H33N5O3Forma y color:SolidPeso molecular:463.57PARP10/15-IN-1
<p>PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].</p>Fórmula:C13H10N2O3SForma y color:SolidPeso molecular:274.3PAD-IN-2
CAS:<p>PAD-IN-2, potent PAD4 inhibitor, IC50 <1 μM; targets autoimmune/cancer disorders.</p>Fórmula:C27H28ClN5O2Forma y color:SolidPeso molecular:490RK-582
CAS:<p>RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.</p>Fórmula:C27H35FN6O3Forma y color:SolidPeso molecular:510.6HDAC1-IN-8
CAS:<p>HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.</p>Fórmula:C22H24N2O4Forma y color:SolidPeso molecular:380.437HDAC/HSP90-IN-4
<p>HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.</p>Fórmula:C20H23N3O6Forma y color:SolidPeso molecular:401.15869TDI-015051
CAS:<p>TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.</p>Fórmula:C22H22FN5O4SForma y color:SolidPeso molecular:471.505(Rac)-RG108
CAS:<p>(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.</p>Fórmula:C19H14N2O4Forma y color:SolidPeso molecular:334.326JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Fórmula:C22H17FN6O2SPureza:98%Forma y color:SolidPeso molecular:448.47AZ0108
CAS:<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Fórmula:C24H20F4N6O2Forma y color:SolidPeso molecular:500.45Dot1L-IN-1
CAS:<p>The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.</p>Fórmula:C32H36ClN9O2SPureza:98%Forma y color:SolidPeso molecular:646.21PARP14 inhibitor 1
CAS:<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Fórmula:C23H27FN4O3Forma y color:SolidPeso molecular:426.484LSD1/2-IN-3
<p>LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.</p>Fórmula:C9H8BrF2NForma y color:SolidPeso molecular:248.07G-631
CAS:<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Fórmula:C19H22F2N6O3Forma y color:SolidPeso molecular:420.41AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H13ClFN5OForma y color:SolidPeso molecular:357.77AZ13824374
<p>AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.</p>Fórmula:C30H39FN8O2Forma y color:SolidPeso molecular:562.68LSD1-IN-13 hydrochloride
CAS:<p>LSD1-IN-13 hydrochloride (7e) is an oral LSD1 inhibitor (IC50: 24.43 nM), promoting differentiation in AML cell lines.</p>Fórmula:C23H30ClN3O2SForma y color:SolidPeso molecular:448.02LSD1-IN-35
CAS:<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Fórmula:C25H26N4O2SForma y color:SolidPeso molecular:446.57SMARCA2/4-ligand-5
CAS:<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Fórmula:C20H13ClN4O3Forma y color:SolidPeso molecular:392.795PARP1-IN-29
CAS:<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Fórmula:C18H16FN3O2Forma y color:SolidPeso molecular:325.34LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Fórmula:C20H18N2OSForma y color:SolidPeso molecular:334.43TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Fórmula:C18H16ClN5Forma y color:SolidPeso molecular:337.81PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Fórmula:C18H18F2N6O3Forma y color:SolidPeso molecular:404.37Menin-MLL inhibitor 4
CAS:<p>Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .</p>Fórmula:C32H38FN7O3Pureza:98%Forma y color:SolidPeso molecular:587.69KAT6A-IN-2
CAS:<p>KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.</p>Fórmula:C23H29N5O5SForma y color:SolidPeso molecular:487.57AMI-408
CAS:<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Fórmula:C20H13Cl2N6NaO5SForma y color:SolidPeso molecular:543.32KAT6A-IN-1
CAS:<p>KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.</p>Fórmula:C23H27N5O5SForma y color:SolidPeso molecular:485.56HLCL-61
CAS:<p>HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).</p>Fórmula:C23H24N2OForma y color:SolidPeso molecular:344.45LSD1-IN-16
<p>LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.</p>Fórmula:C20H18N2OSForma y color:SolidPeso molecular:334.43Bromodomain inhibitor-13
CAS:<p>Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.</p>Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.43CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Fórmula:C18H18N4Forma y color:SolidPeso molecular:290.36SMARCA2-IN-2
CAS:<p>Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.</p>Fórmula:C16H17N3Forma y color:SolidPeso molecular:251.33AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H14FN5OForma y color:SolidPeso molecular:323.32PFI-6-COOH
CAS:<p>PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.</p>Fórmula:C23H21N3O6Forma y color:SolidPeso molecular:435.43NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Fórmula:C22H28N2O3Forma y color:SolidPeso molecular:368.47cis-4-Br-2,5-F2-PCPA
<p>cis-4-Br-2,5-F2-PCPA (S1024) blocks LSD1/LSD2 (Ki: 94 nM/8.4 μM), hinders cancer stem cell growth, raises H3K4me2 in CCRF-CEM cells.</p>Fórmula:C9H8BrF2NForma y color:SolidPeso molecular:248.07YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Fórmula:C19H19F2N7O3Forma y color:SolidPeso molecular:431.40CBP/p300-IN-2
CAS:<p>CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).</p>Fórmula:C27H29F2N7O2Pureza:98%Forma y color:SolidPeso molecular:521.56PRMT5-IN-1
CAS:<p>PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).</p>Fórmula:C19H19ClN4O5Pureza:98%Forma y color:SolidPeso molecular:418.83PARP1/2-IN-4
CAS:<p>PARP1/2-IN-4 (compound 3) is an inhibitor of PARP1/2.</p>Fórmula:C23H30FN5O6Forma y color:SolidPeso molecular:491.51LSD1/HDAC-IN-1
CAS:<p>LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.</p>Fórmula:C18H18N2O4SForma y color:SolidPeso molecular:358.41DCHC
CAS:<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Fórmula:C15H8Cl2O3Forma y color:SolidPeso molecular:307.128SCR-7952
CAS:<p>SCR-7952, a MAT2A inhibitor, is utilized in cancer research.</p>Fórmula:C19H15ClN4OForma y color:SolidPeso molecular:350.80XP-524
CAS:<p>XP-524: BET & EP300 inhibitor, suppresses KRAS tumors in vivo, targets PDAC, boosts immune response.</p>Fórmula:C30H28N6O3SForma y color:SolidPeso molecular:552.65PARP14 inhibitor 2
CAS:<p>PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.</p>Fórmula:C25H32FN3O4SForma y color:SolidPeso molecular:489.60MS8815
CAS:<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Fórmula:C65H87N9O8SForma y color:SolidPeso molecular:1154.51PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Forma y color:SolidPeso molecular:566.63BET-IN-6
CAS:<p>BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.</p>Fórmula:C22H20N2O6SPureza:98%Forma y color:SolidPeso molecular:440.47PRMT5-IN-19
<p>PRMT5-IN-19 is a potent, selective PRMT5 inhibitor with IC50 of 23.9 nM and 47 nM, showing anti-cancer activity by inducing apoptosis.</p>Fórmula:C25H24N4OForma y color:SolidPeso molecular:396.48Itareparib
CAS:<p>Itareparib is a PARP inhibitor with demonstrated antitumor activity.</p>Fórmula:C20H26FN3O2Forma y color:SolidPeso molecular:359.438HIF-1α-IN-4
<p>HIF-1α-IN-4 is an inhibitor of HIF-1α with IC50 of 24 nM in HEK293T cells which has potential antitumor effects.</p>Fórmula:C16H12N2O3Forma y color:SolidPeso molecular:280.28HIF-2α-IN-7
CAS:<p>HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.</p>Fórmula:C18H9F6NO2Forma y color:SolidPeso molecular:385.26TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Forma y color:SolidPeso molecular:489.458(1-Nitroethene-1,2-diyl)dibenzene
CAS:<p>(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.</p>Fórmula:C14H11NO2Forma y color:SolidPeso molecular:225.24Trichostatin A S-isomer
CAS:<p>Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.</p>Fórmula:C17H22N2O3Pureza:98%Forma y color:SolidPeso molecular:302.37OM-153
CAS:<p>OM-153 blocks tankyrase 1 (IC50: 13 nM) and 2 (IC50: 2 nM), stifling WNT signaling and COLO 320DM cell growth.</p>Fórmula:C28H24FN7O2Forma y color:SolidPeso molecular:509.53CM-414
CAS:<p>CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.</p>Fórmula:C23H29N5O4Pureza:98%Forma y color:SolidPeso molecular:439.51RL5a
CAS:<p>RL5a (compound C23) is a novel inhibitor of SETD8.</p>Fórmula:C17H19N3OForma y color:SolidPeso molecular:281.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Fórmula:C18H20F6N4OForma y color:SolidPeso molecular:422.37HDAC-IN-47
<p>HDAC-IN-47: Oral HDAC inhibitor (IC50: 19.75-302.73 nM for HDAC1-8), blocks G2/M, inhibits autophagy, triggers apoptosis, anti-cancer in vivo.</p>Fórmula:C17H20BrN3O4Forma y color:SolidPeso molecular:410.26JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Fórmula:C23H22Cl2N4OForma y color:SolidPeso molecular:441.35HDAC8-IN-2
<p>HDAC8-IN-2 (5o) inhibits both smHDAC8 and hHDAC8 with IC50s of 0.27 μM, 0.32 μM, kills schistosome larvae, and lowers egg laying.</p>Fórmula:C21H16N2O5Forma y color:SolidPeso molecular:376.36Enzomenib
CAS:<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Fórmula:C33H43FN6O3Forma y color:SolidPeso molecular:590.73MI-1481
CAS:<p>MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.</p>Fórmula:C29H30F3N7O2SPureza:98%Forma y color:SolidPeso molecular:597.65HDAC3-IN-3
CAS:<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Fórmula:C26H22N4O2Forma y color:SolidPeso molecular:422.48WW437
<p>WW437 is a histone deacetylase (HDAC) inhibitor that exhibits potent anti-breast cancer activity both in vitro and in vivo.</p>Fórmula:C23H27N5O4Forma y color:SolidPeso molecular:437.49MMSET-IN-1
CAS:<p>MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .</p>Fórmula:C18H29N7O5Pureza:98%Forma y color:SolidPeso molecular:423.47Equisetin
CAS:<p>Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.</p>Fórmula:C22H31NO4Pureza:98%Forma y color:SolidPeso molecular:373.49PAD4-IN-5
CAS:<p>PAD4-IN-5 (Example 18) is a PAD4 inhibitor with an IC50 of ≤10 nM at 50 µM Ca2+ and 101-500 nM at 1 mM Ca2+ against human PAD4 (hPAD4). This compound is applicable in the study of autoimmune diseases such as rheumatoid arthritis (RA).</p>Fórmula:C34H41N7O3Forma y color:SolidPeso molecular:595.734LSD1-IN-18
<p>LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).</p>Fórmula:C31H40N6O2Forma y color:SolidPeso molecular:528.69(2S,3R)-LP99
CAS:<p>(2S,3R)-LP99 is a less active enantiomer of LP99.</p>Fórmula:C26H30ClN3O4SPureza:98%Forma y color:SolidPeso molecular:516.05HDAC-IN-32
<p>HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.</p>Fórmula:C20H23N3O3Forma y color:SolidPeso molecular:353.41AFM-30a hydrochloride
<p>AFM-30a hydrochloride: selective PAD2 inhibitor, EC50 9.5 μM; blocks H3 guanylation, EC50 0.4 μM; used for cancer and autoimmune research.</p>Fórmula:C24H28ClFN6O3Forma y color:SolidPeso molecular:502.97GSK3368715
CAS:<p>GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s</p>Fórmula:C20H38N4O2Pureza:98%Forma y color:SolidPeso molecular:366.54FT001
CAS:<p>FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.</p>Fórmula:C25H29N3O4SPureza:99.9%Forma y color:SolidPeso molecular:467.58NPC26
CAS:<p>NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.</p>Fórmula:C19H23N3O5S2Forma y color:SolidPeso molecular:437.533Aurora/LIM kinase-IN-1
<p>Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.</p>Fórmula:C16H20N6OForma y color:SolidPeso molecular:312.37BRD4 Inhibitor-32
CAS:<p>BRD4 Inhibitor-32 (example 15), a BRD4 inhibitor, is applicable in research pertaining to both acute and chronic kidney disease [1].</p>Fórmula:C26H25N3O3Forma y color:SolidPeso molecular:427.5SGC6870N
CAS:<p>SGC6870N is inactive against PRMT6 and can be used as a negative control. It is the inactive enantiomer of SGC6870.</p>Fórmula:C23H21BrN2O2SPeso molecular:469.39PF-06726304 acetate
CAS:<p>PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity.</p>Fórmula:C24H25Cl2N3O5Pureza:98%Forma y color:SolidPeso molecular:506.38GNE-886
CAS:<p>GNE-886 has a wide range of applications in life science related research.</p>Fórmula:C28H30N6O3Pureza:98%Forma y color:SolidPeso molecular:498.59HuR degrader 2
CAS:<p>HuRdegrader 2 (Compound 3) is a molecular glue that targets and degrades the RNA-binding protein Hu antigen R (HuR), achieving 30% degradation at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 of ≤200 nM. HuRdegrader 2 also shows high affinity for cereblon with an HTRF ratio < 0.02.</p>Fórmula:C20H15N3O3Peso molecular:345.35MAT2A-IN-24
CAS:<p>MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a), with an IC50 value of 20 nM for MAT2a inhibition and an antiproliferative IC50 value of 10 nM for HAP1MTAP–/– cells. MAT2A-IN-24 is applicable in the research of tumor diseases associated with MTAP deficiency.</p>Fórmula:C32H33Cl2N7O2Forma y color:SolidPeso molecular:618.556M-525
CAS:<p>M-525, a potent first-in-class menin-MLL inhibitor, binds at 3 nM IC50 and curbs MLL leukemia cell growth & gene expression.</p>Fórmula:C39H51FN6O5SPureza:98%Forma y color:SolidPeso molecular:734.92Glycyl H-1152 hydrochloride
CAS:<p>Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.</p>Fórmula:C18H26Cl2N4O3SForma y color:SolidPeso molecular:449.39HDAC6-IN-3
<p>HDAC6-IN-3 (Compound 14) is an oral anti-prostate cancer agent, inhibiting HDACs and MAO-A, with IC50 of 0.02-1.54 μM.</p>Fórmula:C19H27N3O3Forma y color:SolidPeso molecular:345.44PARP7-IN-23
CAS:<p>PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells, indicating its potential for cancer research.</p>Fórmula:C27H22F7N5O3Forma y color:SolidPeso molecular:597.484JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Fórmula:C26H36FN5O2Forma y color:SolidPeso molecular:469.59RK-0080552
CAS:<p>RK-0080552 (RK-552) is an inhibitor of the NSD2 histone methyltransferase. It demonstrates significant cytotoxicity against multiple myeloma (MM) cells harboring the t(4;14) translocation. This compound suppresses the IRF4 gene and decreases the dimethylation of histone H3 at lysine 36. RK-0080552 holds promise for research in hematologic malignancies.</p>Fórmula:C12H6N6O2Forma y color:SolidPeso molecular:266.215Octyl-α-hydroxyglutarate
CAS:<p>Octyl-α-hydroxyglutarate (octyl-2-HG) enhances histone methylation and boosts the viability of LMP1-negative nasopharyngeal carcinoma (NPC) cells.</p>Fórmula:C13H24O5Peso molecular:260.33GSK852
<p>GSK852 is a potent, second bromodomain (BD2)-selective, bromo and extra-terminal domain (BET) inhibitor with pIC50 of 7.9.</p>Fórmula:C24H26N2O4Forma y color:SolidPeso molecular:406.47iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Fórmula:C19H15F3N2O2Forma y color:SolidPeso molecular:360.33BRD4/NAMPT-IN-1
CAS:<p>BRD4/NAMPT-IN-1 (Compound A2) exhibits strong inhibitory effects on NAMPT and BRD4, with IC50 values of 35 nM (NAMPT) and 58 nM (BRD4). This compound significantly suppresses the growth and migration of liver cancer cells while promoting apoptosis. Additionally, BRD4/NAMPT-IN-1 demonstrates potent anticancer activity in HCCLM3 xenograft mouse models without noticeable toxicity.</p>Fórmula:C30H30ClN7O2SPeso molecular:588.12RU-0415529
CAS:<p>RU-0415529 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (NSP14), with an IC50 of 356 nM. It inhibits viral RNA methylation and replication by stabilizing the cap-binding pocket through SAH binding. Additionally, RU-0415529 exhibits anti-infective activity in mouse models.</p>Fórmula:C21H29N3O4SForma y color:SolidPeso molecular:419.538PKCiota-IN-1
CAS:<p>PKCiota-IN-1: Strong PKC-ι inhibitor (IC50=2.7 nM); also blocks PKC-α/ε (IC50s=45/450 nM).</p>Fórmula:C25H22FN5OForma y color:SolidPeso molecular:427.47AR/BET protein degrader-1
CAS:<p>AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.</p>Fórmula:C43H44N6O5Peso molecular:724.85HIF-1α-IN-5
<p>HIF-1α-IN-5 is an inhibitor of HIF-1α with an IC 50 value of 24 nM in HEK293T cells that also inhibits the activity of MAO-A.</p>Fórmula:C16H15N3O2Forma y color:SolidPeso molecular:281.31Hesperadin hydrochloride
<p>Hesperadin hydrochloride is an ATP-competitive indolone inhibitor of Aurora A and B, with an IC50 value of 250 nM for Aurora B.</p>Fórmula:C29H33ClN4O3SForma y color:SolidPeso molecular:553.12Triciferol
CAS:<p>Triciferol is a VDR agonist and HDAC antagonist with 1,25D-like potency, affecting gene targets and tubulin, and shows anti-cancer effects in vitro. IC50=87nM.</p>Fórmula:C26H39NO4Forma y color:SolidPeso molecular:429.591NSD2-PWWP1-IN-3
CAS:<p>NSD2-PWWP1-IN-3 (compound 36) is an effective inhibitor of NSD2-PWWP1, with an IC50 value of 8.05 µM. It has potential applications in cancer research.</p>Fórmula:C34H39N5O2Forma y color:SolidPeso molecular:549.706CRV431
CAS:<p>CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).</p>Fórmula:C67H122N12O13Forma y color:SolidPeso molecular:1303.76TK-129
<p>TK-129: Oral KDM5B inhibitor, IC50=44 nM, low-toxicity, cardioprotective, aids in heart disease research.</p>Fórmula:C15H23N5O2Forma y color:SolidPeso molecular:305.385-Ph-IAA-AM
<p>5-Ph-IAA-AM, eggshell-permeable analog of 5-Ph-IAA, boosts protein degradation in embryos, useful for studying proteins in C. elegans.</p>Fórmula:C19H17NO4Forma y color:SolidPeso molecular:323.34(Rac)-Nanatinostat
CAS:<p>(Rac)-Nanatinostat ((Rac)-CHR-3996, example 44) is a potent HDAC inhibitor with an IC50 of less than 330 nM. It exhibits anticancer properties, effectively inhibiting the growth of HeLa, U937, and HUT cells.</p>Fórmula:C20H19FN6O2Forma y color:SolidPeso molecular:394.402Sapintoxin D
CAS:<p>Sapintoxin D is a fluorescent phorbol ester and selective activator of protein kinase C.</p>Fórmula:C30H37NO8Forma y color:SolidPeso molecular:539.62HDAC6-IN-9
CAS:<p>HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.</p>Fórmula:C19H16N2O3Pureza:98.84%Forma y color:SolidPeso molecular:320.34EBET-590
CAS:<p>EBET-590 is a BET inhibitor utilized in cancer research.</p>Fórmula:C26H26N4O3Peso molecular:442.51AZ-3
CAS:<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Fórmula:C20H28FN7Pureza:98%Forma y color:SolidPeso molecular:385.48AMPTX-1
CAS:<p>AMPTX-1 is a molecular glue functioning as a potent, selective, and reversible covalent degrader of BRD9 by recruiting it to the E3 ligase DCAF16.</p>Fórmula:C42H53N5O4Forma y color:SolidPeso molecular:691.901EZH2-IN-12
<p>EZH2-IN-12 (Compound 5) is a potent inhibitor of EZH2, which has potential for studies of CNS malignancies.</p>Fórmula:C23H23Cl2N3O3Forma y color:SolidPeso molecular:460.35CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Fórmula:C18H16ClN5OForma y color:SolidPeso molecular:353.806PARP1-IN-5
<p>PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.</p>Fórmula:C25H24N2O5SForma y color:SolidPeso molecular:464.53Pim-1 kinase inhibitor 3
CAS:<p>Pim-1 kinase inhibitor 3 (Compound H5) is a potent inhibitor of Pim-1 kinase, demonstrating an inhibitory concentration (IC50) of 35.13 nM [1].</p>Fórmula:C20H25N3O2Forma y color:SolidPeso molecular:339.43EN884
CAS:<p>EN884 is a BRD4 degrader that functions through an SKP1 and proteasome-dependent degradation pathway. It is utilized in the synthesis of proteolysis-targeting chimeras (PROTAC).</p>Fórmula:C14H18N2OPeso molecular:230.31BRD4 Inhibitor-17
<p>BRD4 Inhibitor-17: Potent with 0.33 μM IC50; modulates gene expression, may counter arsenic toxicity.</p>Fórmula:C16H16FN3O3SForma y color:SolidPeso molecular:349.38O-Desmethyl Midostaurin
CAS:<p>O-Desmethyl Midostaurin is the active Midostaurin metabolite via cytochrome P450 liver enzyme metabolism.</p>Fórmula:C34H28N4O4Pureza:98%Forma y color:SolidPeso molecular:556.61SMARCA2-IN-6
CAS:<p>SMARCA2-IN-6 is a potent inhibitor of SMARCA2 (also known as BRM), exhibiting an IC50 of less than 5 nM against both SMARCA2 and SMARCA4. Additionally, this compound suppresses the expression of the KRT80 gene in H1299 cells with an IC50 of 26 nM and inhibits the proliferation of SKMEL5 cells carrying a BRG1 mutation with an IC50 value of 13 nM.</p>Fórmula:C10H8ClF2N5OSForma y color:SolidPeso molecular:319.72MS8511
CAS:<p>MS8511: Selective, irreversible G9a/GLP inhibitor. IC50: 100 nM (G9a), 140 nM (GLP). Lowers H3K9me2, anti-proliferative. Useful in cancer/AD/PWS research.</p>Fórmula:C28H41N5O3Forma y color:SolidPeso molecular:495.66PARP7-IN-12
CAS:<p>PARP7-IN-12, a potent inhibitor targeting PARP7, exhibits an IC50 of 7.836 nM. This compound is applicable in cancer research.</p>Fórmula:C23H27ClF3N5O5Forma y color:SolidPeso molecular:545.94FNDR-20123
<p>FNDR-20123: First safe, effective anti-malarial HDAC inhibitor for Plasmodium (IC50: 31 nM) & human HDACs, with nanomolar potency across several subtypes.</p>Fórmula:C21H24ClN5O2Forma y color:SolidPeso molecular:413.9CBP/p300-IN-16
<p>CBP/p300-IN-16 (compound 1) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.61 μM) and LK2 H3K27 (IC50: 2.24 μM).</p>Fórmula:C26H31N3O4Forma y color:SolidPeso molecular:449.54SIRT1-IN-5
CAS:<p>SIRT1-IN-5 (215) is a modulator of the NAD-dependent protein deacetylase SIRT1.</p>Fórmula:C21H17N3O3SForma y color:SolidPeso molecular:391.443Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Fórmula:C25H24N6O3S2Pureza:98%Forma y color:SolidPeso molecular:520.63BET-IN-1
<p>BET-IN-1 is a potent inhibitor of BET, exhibiting good brain permeability and a reasonable metabolic stability.</p>Fórmula:C23H24ClFN4O3SForma y color:SolidPeso molecular:490.98JAK3-IN-11
CAS:<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Fórmula:C23H23N5O2Forma y color:SolidPeso molecular:401.46CARM1-IN-3 dihydrochloride
<p>CARM1-IN-3 dihydrochloride (17b) is a potent CARM1 inhibitor (IC50: 0.07 μM) with selectivity over CARM3 (IC50 >25 μM).</p>Fórmula:C24H34Cl2N4O2Forma y color:SolidPeso molecular:481.46KDOAM-25 trihydrochloride
<p>KDOAM-25 trihydrochloride selectively inhibits KDM5 enzymes, boosts H3K4 methylation, and suppresses MM1S cell growth.</p>Fórmula:C15H28Cl3N5O2Forma y color:SolidPeso molecular:416.77LSD1-IN-19
<p>LSD1-IN-19 is a potent, selective LSD1 inhibitor with Ki of 0.108 μM and 72h IC50 values of 0.17-0.40 μM.</p>Fórmula:C33H42N6O2Forma y color:SolidPeso molecular:554.73CFT8634
CAS:<p>CFT8634 degrades BRD9, for synovial sarcoma and SMARCB1 tumor research, from patent WO2021178920A1.</p>Fórmula:C37H45F3N6O5Forma y color:SolidPeso molecular:710.79P300 bromodomain-IN-1
<p>P300 bromodomain-IN-1 blocks c-Myc, induces G1/G0 arrest, apoptosis. Potent EP300 inhibitor (IC50: 49 nM).</p>Fórmula:C29H31ClN4O4Forma y color:SolidPeso molecular:535.03SCH-1473759
CAS:<p>SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively).</p>Fórmula:C20H26N8OSPureza:98%Forma y color:SolidPeso molecular:426.54QCA570
CAS:<p>QCA570 is an effective BET degrader based on PROTAC (IC50: 10 nM for BRD4 BD1 Protein).</p>Fórmula:C39H33N7O4SPureza:98%Forma y color:SolidPeso molecular:695.79Londamocitinib
CAS:<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Fórmula:C28H31F2N7O4SPureza:98.64% - 99.56%Forma y color:SolidPeso molecular:599.65MAO A/HDAC-IN-1
<p>MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.</p>Fórmula:C21H24ClN3O3Forma y color:SolidPeso molecular:401.89BRD4 D1-IN-2
<p>BRD4 D1-IN-2 (compound 26), a BRD4 D1 inhibitor, IC50 <0.092 μM, 15 nM affinity, >500x selectivity over BRD2 D1/BRD4 D2.</p>Fórmula:C33H39F3N6OForma y color:SolidPeso molecular:592.7HDAC6-IN-12
<p>HDAC6-IN-12 is a potent inhibitor of HDAC6 that binds in the DNA chain, causing DNA damage and exhibiting anticancer effects that can be used in cancer research</p>Fórmula:C24H39F2N3O5Forma y color:SolidPeso molecular:487.58Balanol
CAS:<p>Balanol is an ATP-competitive Protein Kinase C and Protein Kinase A inhibitor.</p>Fórmula:C28H26N2O10Forma y color:SolidPeso molecular:550.51Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.42Tyk2-IN-14
CAS:<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Fórmula:C22H21N9O2Forma y color:SolidPeso molecular:443.46PARP-1-IN-1
<p>PARP-1-IN-1: Selective, oral PARP-1 inhibitor with 0.96 nM IC50; well-tolerated and effective in single-dose MDA-MB-436 model.</p>Fórmula:C23H25FN4OForma y color:SolidPeso molecular:392.47B026
CAS:<p>B026: Oral p300/CBP HAT inhibitor, IC50: p300 1.8 nM, CBP 9.5 nM; targets AR+ prostate cancer cells.</p>Fórmula:C27H23F4N5O4Forma y color:SolidPeso molecular:557.5Pim-1 kinase inhibitor 6
CAS:<p>Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].</p>Fórmula:C21H10BrCl2N3Forma y color:SolidPeso molecular:455.13DS44470011
CAS:<p>DS44470011 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) with oral bioavailability. It enhances the release of erythropoietin (EPO) from cells and is utilized in research related to renal anemia.</p>Fórmula:C21H19N3O4Forma y color:SolidPeso molecular:377.39IBL-302
CAS:<p>IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].</p>Fórmula:C25H18FN5O4S3Forma y color:SolidPeso molecular:567.64SE-7552
CAS:<p>SE-7552, a derivative of 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO), serves as an orally active, highly selective non-hydroxamate HDAC6 inhibitor, boasting an IC50 of 33 nM. It exhibits over 850-fold selectivity against all other known HDAC isozymes. Demonstrating efficacy in vivo, SE-7552 effectively inhibits the growth of multiple myeloma. Additionally, it functions as an anti-obesity agent in diet-induced obese mice [1] [2].</p>Fórmula:C15H12F3N5OForma y color:SolidPeso molecular:335.28Menin-MLL inhibitor 26
CAS:<p>Menin-MLL inhibitor 26: Active reference, inhibits cell growth, used in leukemia research.</p>Fórmula:C27H29F3N6O3SForma y color:SolidPeso molecular:574.62EED ligand 1
<p>EED ligand 1: potent PRC2 inhibitor targeting EED subunit.</p>Fórmula:C19H19FN8OForma y color:SolidPeso molecular:394.41MDH1/2-IN-1
CAS:<p>MDH1/2-IN-1 is an MDH1/2 inhibitor with IC50 values of 1.07 nM and 1.06 nM, respectively. It suppresses mitochondrial respiration and the HIF-1α pathway. MDH1/2-IN-1 exhibits significant antitumor potential and offers new avenues for developing drugs targeting cancer metabolism.</p>Fórmula:C25H33NO4Forma y color:SolidPeso molecular:411.534JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Fórmula:C17H23N7OForma y color:SolidPeso molecular:341.41WDR5-IN-5
CAS:<p>WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.</p>Fórmula:C29H29F3N6OForma y color:SolidPeso molecular:534.58Aurora inhibitor 1
CAS:<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Fórmula:C23H25N9SPureza:98%Forma y color:SolidPeso molecular:459.57BET-IN-8
<p>BET-IN-8 (Compound 27) is a potent inhibitor of BET (Ki: 0.83 μM, Kd: 0.571 μM), which ameliorates LPS-induced sepsis in vivo.BET-IN-8 has shown potential in</p>Fórmula:C22H21N3O4SForma y color:SolidPeso molecular:423.48GSK8814
CAS:<p>GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan).</p>Fórmula:C28H35F2N5O3Pureza:98%Forma y color:SolidPeso molecular:527.61Basroparib
CAS:<p>Basroparib is an inhibitor of ribose polymerase (PARP) and has shown antitumour effects.</p>Fórmula:C18H21F2N7O3Forma y color:SolidPeso molecular:421.4BRD-7880
CAS:<p>BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C.</p>Fórmula:C32H38N4O7Forma y color:SolidPeso molecular:590.67PRMT5-IN-1 hydrochloride
<p>PRMT5 IN-1 hydrochloride is a potent PRMT5 inhibitor (IC50: 11 nM), forms covalent adduct with C449, and converts to an aldehyde in vivo.</p>Fórmula:C19H20Cl2N4O5Forma y color:SolidPeso molecular:455.29DS17701585
<p>DS17701585: Oral EP300/CBP inhibitor; potent on CBP, EP300, H3K27, & SOX2; useful for cancer research.</p>Fórmula:C24H26N4O5SForma y color:SolidPeso molecular:482.55Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Fórmula:C21H25F2N7OForma y color:SolidPeso molecular:429.47BRD4-BD1/2-IN-2
CAS:<p>BRD4-BD1/2-IN-2 inhibits BRD4 BD1/BD2 with IC50 <300 nM/<0.5 nM (WO2021233371A1).</p>Fórmula:C30H33N5O4Forma y color:SolidPeso molecular:527.61HDAC2-IN-1
<p>HDAC2-IN-1 is an oral HDAC2 inhibitor (IC50: 0.5 μM), crosses the blood-brain barrier, and inhibits HDAC1 and HDAC8.</p>Fórmula:C22H23ClN4OSForma y color:SolidPeso molecular:426.96PRMT5-IN-18
CAS:<p>PRMT5-IN-18 (Compound 002) is a potent inhibitor of PRMT5 and can be used in the study of PRMT5-mediated diseases, such as tumours.</p>Fórmula:C32H42N4O4Forma y color:SolidPeso molecular:546.70HDAC-IN-33
<p>HDAC-IN-33 inhibits HDAC1/2/6 (IC50: 24/46/47 nM), exhibits potent antitumor activity in vitro and in vivo, and activates antitumor immunity.</p>Fórmula:C21H25N3O3Forma y color:SolidPeso molecular:367.44MTL-CEBPA
<p>MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.</p>Forma y color:SolidAurora A inhibitor 1
CAS:<p>Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)</p>Fórmula:C25H28ClF2N5O2Forma y color:SolidPeso molecular:503.97ORIC-944
CAS:<p>ORIC-944 is an orally available, selective variant of PRC2 with anticancer activity for the study of prostate cancer.</p>Fórmula:C26H25FN6OPureza:98.08%Forma y color:SolidPeso molecular:456.52Pocenbrodib
CAS:<p>Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.</p>Fórmula:C28H32FN3O6Pureza:98.48% - 99.54%Forma y color:SolidPeso molecular:525.57GSK3368715 dihydrochloride
CAS:<p>GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is a PRMTs inhibitor , with anticancer activity, for the study of advanced solid tumors.</p>Fórmula:C20H40Cl2N4O2Pureza:99.66% - 99.66%Forma y color:SolidPeso molecular:439.46LLY-283
CAS:<p>LLY-283, PRMT5 inhibitor, IC50 22 nM, Kd 6 nM, oral, selective, with antitumor effects.</p>Fórmula:C17H18N4O4Pureza:99.49%Forma y color:SolidPeso molecular:342.35DN02
<p>DN02: a potent, selective BRD8(1) bromodomain probe; Ki=32 nM; 30x more affine than BRD8(2).</p>Fórmula:C22H24FN3O3Pureza:98.22% - 99.74%Forma y color:SolidPeso molecular:397.44EZM0414
CAS:<p>EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay.</p>Fórmula:C22H29FN4O2Pureza:99.58%Forma y color:SolidPeso molecular:400.49INCB054329
CAS:<p>INCB054329 is a BET inhibitor targeting BRD2/3/4 and BRDT with IC50s ranging from 1-119 nM.</p>Fórmula:C19H16N4O3Pureza:99.52%Forma y color:SolidPeso molecular:348.36AMG-193
CAS:<p>AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.</p>Fórmula:C22H19F3N4O3Pureza:99.52%Forma y color:SolidPeso molecular:444.41BRD0639
CAS:<p>BRD0639 is a first-in-class PRMT5-substrate interaction inhibitor for PBM-dependent PRMT5 activity studies.</p>Fórmula:C21H22ClN5O4SPureza:99.85%Forma y color:SolidPeso molecular:475.95Sinefungin
CAS:<p>Sinefungin (Adenosyl-Ornithine) is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral</p>Fórmula:C15H23N7O5Pureza:98.12%Forma y color:SolidPeso molecular:381.39JDTic
CAS:<p>JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.</p>Fórmula:C28H39N3O3Forma y color:SolidPeso molecular:465.63
